68 related articles for article (PubMed ID: 20727598)
1. Selective recognition and elimination of nicotinic acetylcholine receptor-reactive B cells by a recombinant fusion protein AChR-Fc in myasthenia gravis in vitro.
Chang T; Lin H; Gao J; Li W; Xu J; Sun CJ; Li H; Li FF; Song Y; Ye J; Li ZY
J Neuroimmunol; 2010 Oct; 227(1-2):35-43. PubMed ID: 20727598
[TBL] [Abstract][Full Text] [Related]
2. B-T lymphocyte interactions in experimental autoimmune myasthenia gravis: antigen presentation by rat/mouse hybridoma lines secreting monoclonal antibodies against the nicotinic acetylcholine receptor.
Zhang YP; Tzartos SJ; Wekerle H
Eur J Immunol; 1988 Feb; 18(2):211-8. PubMed ID: 2450756
[TBL] [Abstract][Full Text] [Related]
3. A Novel Fusion Protein, AChR-Fc, Ameliorates Myasthenia Gravis by Neutralizing Antiacetylcholine Receptor Antibodies and Suppressing Acetylcholine Receptor-Reactive B Cells.
Homma M; Uzawa A; Tanaka H; Kawaguchi N; Kanai T; Nakajima K; Narita M; Hara Y; Maruyama H; Ogawa Y; Himuro K; Kuwabara S
Neurotherapeutics; 2017 Jan; 14(1):191-198. PubMed ID: 27677608
[TBL] [Abstract][Full Text] [Related]
4. [Fc Fusion Protein as a Novel Treatment for Myasthenia Gravis].
Uzawa A; Yamashita J; Kuwabara S
Brain Nerve; 2019 May; 71(5):525-530. PubMed ID: 31089000
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis.
Lennon VA; Lambert EH; Leiby KR; Okarma TB; Talib S
J Immunol; 1991 Apr; 146(7):2245-8. PubMed ID: 2005394
[TBL] [Abstract][Full Text] [Related]
6. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
7. B-T lymphocyte interactions in experimental autoimmune myasthenia gravis: autoantibody mediated up-regulation of the response of acetylcholine receptor-specific T lymphocytes.
Zhang Y; Tzartos S
Immunology; 1992 Dec; 77(4):571-6. PubMed ID: 1283599
[TBL] [Abstract][Full Text] [Related]
8. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Qiao J; Melms A; Link H
Cell Immunol; 1993 Dec; 152(2):394-404. PubMed ID: 8258147
[TBL] [Abstract][Full Text] [Related]
9. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.
Im SH; Barchan D; Fuchs S; Souroujon MC
J Clin Invest; 1999 Dec; 104(12):1723-30. PubMed ID: 10606626
[TBL] [Abstract][Full Text] [Related]
10. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats.
Zhang GX; Ma CG; Xiao BG; Bakhiet M; Link H; Olsson T
Eur J Immunol; 1995 May; 25(5):1191-8. PubMed ID: 7774622
[TBL] [Abstract][Full Text] [Related]
11. Preferential use of a T cell receptor V beta gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice.
Infante AJ; Levcovitz H; Gordon V; Wall KA; Thompson PA; Krolick KA
J Immunol; 1992 Jun; 148(11):3385-90. PubMed ID: 1375242
[TBL] [Abstract][Full Text] [Related]
12. Clonotypic analysis of anti-acetylcholine receptor antibodies from experimental autoimmune myasthenia gravis-sensitive Lewis rats and experimental autoimmune myasthenia gravis-resistant Wistar Furth rats.
Zoda T; Yeh TM; Krolick KA
J Immunol; 1991 Jan; 146(2):663-70. PubMed ID: 1987281
[TBL] [Abstract][Full Text] [Related]
13. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls.
Link H; Olsson O; Sun J; Wang WZ; Andersson G; Ekre HP; Brenner T; Abramsky O; Olsson T
J Clin Invest; 1991 Jun; 87(6):2191-6. PubMed ID: 1904073
[TBL] [Abstract][Full Text] [Related]
14. Induction of interferon-gamma, interleukin-4, and transforming growth factor-beta in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Link H; Ljungdahl A; Höjeberg B; Link J; He B; Qiao J; Melms A; Olsson T
Cell Immunol; 1994 Sep; 157(2):353-68. PubMed ID: 7520837
[TBL] [Abstract][Full Text] [Related]
15. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis.
Yoshikawa H; Lambert EH; Walser-Kuntz DR; Yasukawa Y; McCormick DJ; Lennon VA
J Immunol; 1997 Aug; 159(3):1570-7. PubMed ID: 9233656
[TBL] [Abstract][Full Text] [Related]
16. Novel immunotoxin: a fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis.
Hossann M; Li Z; Shi Y; Kreilinger U; Büttner J; Vogel PD; Yuan J; Wise JG; Trommer WE
Protein Expr Purif; 2006 Mar; 46(1):73-84. PubMed ID: 16230023
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of an acetylcholine receptor-transferrin fusion protein for the treatment of myasthenia gravis.
Keefe D; Parng C; Lundberg D; Ray S; Martineau-Bosco J; Leng C; Tzartos S; Powell J; Concino M; Heartlein M; Lamsa J; Josiah S
Autoimmunity; 2010 Dec; 43(8):628-39. PubMed ID: 20402568
[TBL] [Abstract][Full Text] [Related]
18. Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates.
Killen JA; Lindstrom JM
J Immunol; 1984 Nov; 133(5):2549-53. PubMed ID: 6332854
[TBL] [Abstract][Full Text] [Related]
19. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
20. The role of B-cells in experimental myasthenia gravis in mice.
Wang HB; Li H; He B; Bakheit M; Levi M; Wahren B; Berglöf A; Sandstedt K; Link H; Shi FD
Biomed Pharmacother; 1999 Jun; 53(5-6):227-33. PubMed ID: 10424244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
